Cargando…
Global variation of risk thresholds for initiating statins for primary prevention of cardiovascular disease: a benefit-harm balance modelling study
BACKGROUND: We previously showed that the 10-year cardiovascular disease (CVD) risk threshold to initiate statins for primary prevention depends on the baseline CVD risk, age, sex, and the incidence of statin-related harm outcome and competing risk for non-CVD death. As these factors appear to vary...
Autores principales: | Yebyo, Henock G., Zappacosta, Sofia, Aschmann, Hélène E., Haile, Sarah R., Puhan, Milo A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7495829/ https://www.ncbi.nlm.nih.gov/pubmed/32942999 http://dx.doi.org/10.1186/s12872-020-01697-6 |
Ejemplares similares
-
Net benefit of statins for primary prevention of cardiovascular
disease in people 75 years or older: a benefit–harm balance modeling
study
por: Yebyo, Henock G., et al.
Publicado: (2019) -
Should statin guidelines consider patient preferences? Eliciting preferences of benefit and harm outcomes of statins for primary prevention of cardiovascular disease in the sub-Saharan African and European contexts
por: Yebyo, Henock G., et al.
Publicado: (2018) -
Older adult preferences regarding benefits and harms of statin and aspirin therapy for cardiovascular primary prevention()
por: Wang, Frances M., et al.
Publicado: (2023) -
Large-scale prevention trials could provide stronger evidence for decision-makers: Opportunities to design and report with a focus on the benefit–harm balance
por: Aschmann, Hélène E, et al.
Publicado: (2022) -
Fingolimod versus interferon beta 1-a: Benefit–harm assessment
approach based on TRANSFORMS individual patient data
por: Spanu, Alessandra, et al.
Publicado: (2022)